Want to see AU:PYC full AI Analyst Report?
Top Page
PYC Therapeutics Limited
(Sydney:PYC)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$2.50
â–²(20.19% Upside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by weak financial performance (persistent losses, negative cash flow, and revenue dropping to zero in FY2026) despite a relatively strong, low-debt balance sheet. Technicals are supportive with an established uptrend, but overbought signals temper the near-term outlook. Valuation offers limited support given the negative P/E and no dividend data.
Positive Factors
Low leverage and stronger capitalization
Minimal leverage lowers solvency pressure for a development-stage biotechnology company and preserves financial flexibility. The increase in assets and equity also indicates meaningful capitalization and liquidity support, giving PYC a stronger base from which to fund ongoing research and development.
Negative Factors
Persistent large operating losses
Ongoing large losses show that PYC has not yet converted its platform and development activities into profitable operations. Continued negative earnings can constrain internal reinvestment, reduce financial resilience, and make progress dependent on successful future commercial or financing outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and stronger capitalization
Minimal leverage lowers solvency pressure for a development-stage biotechnology company and preserves financial flexibility. The increase in assets and equity also indicates meaningful capitalization and liquidity support, giving PYC a stronger base from which to fund ongoing research and development.
Read all positive factors
PYC Therapeutics Limited (PYC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.38B
Dividend YieldN/A
Average Volume (3M)2.85M
Price to Earnings (P/E)―
Beta (1Y)1.78
Revenue GrowthN/A
EPS Growth39.63%
CountryAU
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding983,510,440
10 Day Avg. Volume4,582,648
30 Day Avg. Volume2,849,630
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-27.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.80Price Target Upside82.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.09
Revenue Forecast (FY)AU$5.00M
PYC Therapeutics Limited Business Overview & Revenue Model
Company Description
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical tr...
PYC Therapeutics Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 23.49M | 22.06M | 15.81M | 16.04M |
| Gross Profit | -1.20M | 23.49M | 22.06M | 14.92M | 15.20M |
| EBITDA | -81.47M | -52.88M | -54.55M | -38.25M | -29.39M |
| Net Income | -43.34M | -50.30M | -37.73M | -22.79M | -13.86M |
Balance Sheet | |||||
| Total Assets | 708.52M | 183.28M | 91.24M | 37.17M | 45.35M |
| Cash, Cash Equivalents and Short-Term Investments | 447.56M | 153.05M | 66.87M | 15.57M | 29.11M |
| Total Debt | 624.99K | 1.02M | 1.11M | 315.49K | 943.77K |
| Total Liabilities | 15.18M | 13.27M | 10.18M | 8.72M | 5.15M |
| Stockholders Equity | 693.33M | 169.57M | 80.50M | 27.75M | 39.35M |
Cash Flow | |||||
| Free Cash Flow | -45.05M | -52.54M | -38.90M | -24.91M | -22.17M |
| Operating Cash Flow | -44.52M | -51.56M | -38.59M | -24.42M | -21.78M |
| Investing Cash Flow | -616.16M | -975.40K | -307.04K | -477.12K | 32.68M |
| Financing Cash Flow | 563.22M | 138.66M | 90.19M | 11.44M | -182.36K |
PYC Therapeutics Limited Technical Analysis
Positive
2.08
Price Trends
1.96
Positive
1.66
Positive
1.55
Positive
Market Momentum
0.14
Positive
56.45
Neutral
51.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PYC, the sentiment is Positive. The current price of 2.08 is below the 20-day moving average (MA) of 2.28, above the 50-day MA of 1.96, and above the 200-day MA of 1.55, indicating a bullish trend. The MACD of 0.14 indicates Positive momentum. The RSI at 56.45 is Neutral, neither overbought nor oversold. The STOCH value of 51.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PYC.
PYC Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.60B | 128.11 | 6.03% | 0.00% | -68.00% | -86.31% | |
55 Neutral | AU$2.38B | -39.42 | -10.31% | ― | ― | 39.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$386.41M | -44.74 | -42.35% | ― | 145.32% | 25.75% | |
45 Neutral | AU$880.47M | -7.59 | -51.15% | ― | ― | -44.83% | |
43 Neutral | AU$108.55M | -7.14 | 84.67% | ― | ― | 42.51% |
* Healthcare Sector Average
AU:PYC
PYC Therapeutics Limited
2.32
1.13
94.79%
AU:NEU
Neuren Pharmaceuticals Limited
20.21
1.61
8.66%
AU:SPL
Starpharma Holdings Limited
0.79
0.66
548.76%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.24
-0.89
-28.43%
AU:RCE
Recce Pharmaceuticals Ltd.
0.37
-0.04
-9.76%
PYC Therapeutics Limited Corporate Events
Index Rebalance Adds PYC Therapeutics to S&P/ASX 300
Sep 4, 2026
SP Dow Jones Indices has announced its September 2026 quarterly rebalance of the SP/ASX index series, bringing several changes across the SP/ASX 50, 100, 200 and 300 benchmarks while leaving the SP/ASX 20 unchanged. Among the additions, PYC Therap...
PYC Therapeutics Updates Investors, Emphasizes Early-Stage Status and Risks
Sep 3, 2026
PYC Therapeutics has released an investor presentation outlining an update on its business and drug development pipeline, emphasizing that the materials are a corporate communication aid and should be read alongside its past and future market anno...
PYC Therapeutics to Showcase ADOA Drug Data at NOSA 2026
Sep 2, 2026
PYC Therapeutics Limited, a clinical-stage biotechnology company listed on the ASX, specializes in precision RNA therapies for monogenic genetic diseases with no existing treatments and employs a proprietary delivery platform to boost drug potency...
Retail Employees Super Fund Exits Substantial Holding in PYC Therapeutics
Sep 2, 2026
Retail Employees Superannuation Pty Ltd, acting as trustee of the Retail Employee Superannuation Trust, has disclosed that it ceased to be a substantial shareholder in PYC Therapeutics Ltd as of 31 August 2026. The change followed a series of shar...
PYC Therapeutics Reports Positive Early Safety Data for PKD Drug PYC-003
Aug 30, 2026
PYC Therapeutics Limited is a precision medicine biotech focused on genetic diseases with no existing treatments, operating clinical-stage programs in Australia and the U.S. Its lead renal candidate, PYC-003, targets the underlying cause of Polycy...
PYC details evolving governance framework aligned with ASX principles
Aug 28, 2026
PYC Therapeutics has detailed its corporate governance framework for the 12 months to 30 June 2026, confirming adoption of the ASX Corporate Governance Council’s latest principles where appropriate for its size and operations. The board has ...
PYC Therapeutics Files 2026 Corporate Governance Statement with ASX
Aug 28, 2026
PYC Therapeutics Limited is an Australia-listed biotechnology company that discloses its governance and investor information via its website, in line with ASX regulatory requirements. The company’s operations are framed by the ASX Corporate ...
PYC Therapeutics Details Governance and Operations in 2026 Annual Report
Aug 28, 2026
PYC Therapeutics released its 2026 Annual Report, outlining its current corporate structure, including a board led by Chairperson Peter Coleman and CEO Dr Rohan Hockings, and detailing its registered office, principal place of business, and share ...
PYC Therapeutics Narrows Loss and Strengthens Balance Sheet in FY2026
Aug 28, 2026
PYC Therapeutics has lodged its preliminary financial report for the year ended 30 June 2026, showing income from ordinary activities rising 51.6% to $39.7 million while the net loss after tax narrowed 13.8% to $43.3 million. The company reported ...
PYC Therapeutics Schedules September Investor Webinar to Detail Pipeline Progress
Aug 17, 2026
PYC Therapeutics will host an investor webinar on 4 September 2026 to brief shareholders on progress across its pipeline of investigational RNA-based drug candidates during calendar year 2026. The event, held in Perth with an online option, unders...
PYC Therapeutics boosts CEO equity incentives with major option and rights grants
Aug 14, 2026
PYC Therapeutics has updated the market on changes to Chief Executive Dr Rohan Hockings’ interests, following the issue of a substantial package of unquoted options under the company’s long term incentive plan. The new options, expirin...
PYC Therapeutics advances genetic disease pipeline and strengthens corporate footing
Jul 28, 2026
PYC advanced its polycystic kidney disease program into a Phase 1b multiple ascending dose study in patients, after safety review approval for repeat dosing, and subsequently secured clearance to escalate to a higher dose cohort and to run an open...
PYC Therapeutics Gains Safety Clearance to Escalate Dosing in PKD Trial
Jul 21, 2026
PYC Therapeutics has received Safety Review Committee clearance to escalate dosing of its Polycystic Kidney Disease drug candidate PYC-003 to 2.4 mg/kg in an ongoing Phase 1b multiple ascending dose study. The decision follows review of safety and...
PYC Therapeutics Secures Shareholder Approval at Extraordinary General Meeting
Jul 15, 2026
PYC Therapeutics Limited announced that all resolutions put to shareholders at its Extraordinary General Meeting on 15 July 2026 were passed following a poll. The meeting considered resolutions outlined in a notice dated 12 June 2026, and the comp...
PYC Therapeutics Wins Long-Term U.S. Patents for Lead RNA Drug Candidates
Jul 7, 2026
PYC Therapeutics has secured key U.S. composition of matter patents for its three clinical-stage RNA drug candidates, covering therapies for Polycystic Kidney Disease, Autosomal Dominant Optic Atrophy and Retinitis Pigmentosa Type 11. The grants e...
PYC Therapeutics Strengthens Financial Leadership with New CFO Appointment
Jul 6, 2026
PYC Therapeutics has appointed Thomas Ulmer as its new chief financial officer, adding a seasoned finance executive with two decades of international leadership experience across biotechnology, pharmaceuticals and healthcare. Ulmer previously serv...
PYC Therapeutics Announces Lapse of 700,000 Unlisted Options
Jun 17, 2026
PYC Therapeutics Limited has reported the lapse of 700,000 unlisted options, comprising 400,000 options exercisable at $3.00 expiring in November 2028 and 300,000 options exercisable at $2.52 expiring in January 2029. The options ceased to exist o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.